Table 1 General characteristics of subjects.
All patients | No OAC | OAC | P-value | |
|---|---|---|---|---|
N | 7395 | 1895 | 5500 | |
Age, mean (SD) | 73.1 (10.2) | 74.3 (10.2) | 72.7 (10.1) | < 0.001 |
Male, n (%) | 4008 (54.2) | 993 (52.4) | 3015 (54.8) | 0.07 |
Arrival time, n (%) | 0.01 | |||
within 12 h | 5968 (80.7) | 1559 (82.3) | 4409 (80.2) | |
12–24 h | 770 (10.4) | 163 (8.6) | 607 (11.0) | |
24–48 h | 657 (8.9) | 173 (9.1) | 484 (8.8) | |
Prestroke mRS 0–1, n (%) | 6296 (85.1) | 1531 (80.8) | 4765 (86.6) | < 0.001 |
BMI, mean (SD) | 23.5 (3.5) | 23.4 (3.4) | 23.6 (3.5) | 0.12 |
Baseline NIHSS, median (IQR) | 5 (2—10) | 8 (3—13) | 5 (2—9) | < 0.001 |
Risk factors, n (%) | ||||
Previous TIA | 155 (2.1) | 33 (1.7) | 122 (2.2) | 0.21 |
Previous stroke | 1816 (24.6) | 466 (24.6) | 1350 (24.5) | 0.97 |
Previous PAD | 49 (0.7) | 13 (0.7) | 36 (0.7) | 0.88 |
Previous CAD | 1031 (13.9) | 268 (14.1) | 763 (13.9) | 0.77 |
Hypertension | 5209 (70.4) | 1378 (72.7) | 3831 (69.7) | 0.01 |
Diabetes | 2136 (28.9) | 602 (31.8) | 1534 (27.9) | 0.001 |
Dyslipidemia | 2030 (27.5) | 433 (22.8) | 1597 (29.0) | < 0.001 |
Smoking | 1329 (18.0) | 333 (17.6) | 996 (18.1) | 0.60 |
Congestive heart failure | 319 (4.3) | 77 (4.1) | 242 (4.4) | 0.53 |
Medication history | ||||
Prior antiplatelet use | 2668 (36.1) | 723 (38.2) | 1945 (35.4) | 0.03 |
Prior anticoagulant use | 1251 (16.9) | 193 (10.2) | 1058 (19.2) | < 0.001 |
Prior antihypertensive use | 4472 (60.5) | 1161 (61.3) | 3311 (60.2) | 0.41 |
Prior statin use | 1694 (22.9) | 378 (19.9) | 1316 (23.9) | 0.0004 |
Prior antidiabetic use | 1617 (21.9) | 470 (24.8) | 1147 (20.9) | 0.0003 |
Laboratory findings, mean (SD) | ||||
WBC count, 103/µL | 8.12 (2.86) | 8.62 (3.28) | 7.94 (2.68) | < 0.001 |
Creatinine, mg/dl | 1.05 (0.87) | 1.08 (0.88) | 1.04 (0.87) | 0.09 |
Hemoglobin, g/dl | 13.5 (2.0) | 13.2 (2.1) | 13.6 (1.9) | < 0.001 |
Platelet count, 103/µL | 207.2 (64.3) | 206.8 (69.0) | 207.3 (62.6) | 0.78 |
Low-density lipoprotein, mg/dl | 97.9 (32.3) | 98.2 (32.9) | 97.7 (32.1) | 0.59 |
PT, INR | 1.16 (0.40) | 1.15 (0.42) | 1.17 (0.40) | 0.07 |
Glucose, mg/dl | 138.5 (52.0) | 143.7 (52.6) | 136.7 (51.7) | < 0.001 |
SBP, mmHg | 143.0 (25.8) | 144.3 (27.6) | 142.6 (25.2) | 0.02 |
LAD, n (%) | < 0.001 | |||
no stenosis | 3190 (43.1) | 667 (35.2) | 2523 (45.9) | |
mild < 50% | 368 (5.0) | 77 (4.1) | 291 (5.3) | |
moderate > 50% | 744 (10.1) | 216 (11.4) | 528 (9.6) | |
occlusion | 3093 (41.8) | 935 (49.3) | 2158 (39.2) | |
Multiple lesions, n (%) | 1255 (17.0) | 384 (20.3) | 871 (15.8) | < 0.001 |
Recanalization therapy | 0.0001 | |||
no | 5290 (71.5) | 1281 (67.6) | 4009 (72.9) | |
IVT | 1129 (15.3) | 319 (16.8) | 810 (14.7) | |
IAT | 470 (6.4) | 142 (7.5) | 328 (6.0) | |
IV + IAT | 506 (6.8) | 153 (8.1) | 353 (6.4) | |
CHA2DS2-VASc, med (IQR)* | 3 (2—5) | 4 (2—5) | 3 (2—5) | < 0.0001 |
Stroke mechanism | 0.0001 | |||
Other than CE | 1494 (20.2) | 440 (23.2) | 1054 (19.2) | |
CE | 5901 (79.8) | 1455 (76.8) | 4446 (80.8) | |
In-hospital treatment | ||||
Antidiabetics | 1454 (19.7) | 340 (17.9) | 1114 (20.3) | 0.03 |
Anti-HTN | 3342 (45.2) | 744 (39.3) | 2598 (47.2) | < 0.001 |
Statin | 5941 (80.3) | 1250 (66.0) | 4691 (85.3) | < 0.001 |
